HK Stock Market Move | JACOBIO-B(01167) surged more than 6% after its performance report. Breakthroughs in multiple points in the research and development pipeline are expected in 2025. JACOBIO is collaborating with AstraZeneca to develop JAB-23E73.

JACOBIO-B (01167) rose more than 6% after the performance announcement, as of the press release, it rose 2.23% to 6.93 Hong Kong dollars, with a turnover of 82.854 million Hong Kong dollars. On the news side, on March 10, JACOBIO-B announced its performance for 2025, with revenue of about 53.5 million yuan, R&D expenses decreased by 42.9% year-on-year to 188.6 million yuan, administrative expenses decreased by 20.2% year-on-year to 34.4 million yuan, and net loss narrowed by 6.25% year-on-year to about 146 million yuan. The company has a strong patent portfolio to protect its candidate drugs and technologies. As of December 31, 2025, the company has 380 valid patents or patent applications filed globally, with 146 patents granted or allowed in major markets worldwide. During the year, the company entered into a license and collaboration agreement with AstraZeneca AB to jointly develop and commercialize the pan-KRAS inhibitor JAB-23E73. Under the license and collaboration agreement and subject to its terms and conditions, Jakobi has the right to receive a prepayment of $100 million from AstraZeneca and is eligible to receive additional milestone payments upon achieving certain development, regulatory, and commercial milestones, with a total potential cost of up to $1.915 billion. In addition, if the licensed product is successfully commercialized, Jakobi will have the right to receive tiered royalty fees based on net sales of the licensed product.